HEALTH-RELATED QUALITY OF LIFE (HRQOL) OF ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS TREATED IN SECOND LINE WITH ALECTINIB

被引：0
|
作者：
Greillier, L. [1 ]
Tuzelet, V [2 ]
Cadranel, J. [3 ]
Thiberville, L. [4 ]
Chouaid, C. [5 ]
Girard, N. [6 ]
Cortot, A. B. [7 ]
Felicio, H. [8 ]
Weber, V [8 ]
Pau, D. [8 ]
机构：
[1] APHM, Marseille, France
[2] Keyrus Biopharma, La Chapelle Sur Erdre, France
[3] Hop Tenon, Paris, France
[4] Hop Charles Nicolle, Rouen, France
[5] Creteil Univ Hosp, Dept Chest Med, Creteil, France
[6] Inst Curie, Paris, France
[7] CHRU Lille, Lille, France
[8] Roche, Boulogne, France
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN17
引用
收藏
页码：S423 / S423
页数：1
相关论文
共 50 条
  • [41] Ceritinib-a second-generation ALK inhibitor overcoming resistance in ALK-rearranged non-small cell lung cancer
    Rothschild, Sacha I.
    TRANSLATIONAL LUNG CANCER RESEARCH, 2014, 3 (06) : 379 - 381
  • [42] Alectinib: a selective, next-generation ALK inhibitor for treatment of ALK-rearranged non-small-cell lung cancer
    Santarpia, Mariacarmela
    Altavilla, Giuseppe
    Rosell, Rafael
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2015, 9 (03) : 255 - 268
  • [43] Comparing four different ALK antibodies with manual immunohistochemistry (IHC) to screen for ALK-rearranged non-small cell lung cancer (NSCLC)
    Shen, Qin
    Wang, Xuan
    Yu, Bo
    Shi, Shanshan
    Liu, Biao
    Wang, Yanfen
    Xia, Qiuyuan
    Rao, Qiu
    Zhou, Xiaojun
    LUNG CANCER, 2015, 90 (03) : 492 - 498
  • [44] SHP2 inhibition restores sensitivity to ALK inhibition in resistant ALK-rearranged non-small cell lung cancer (NSCLC)
    Dardaei, Leila
    Wang, Hui Qin
    Fordjour, Paul
    Singh, Manrose
    Kerr, Grainne
    Yoda, Satoshi
    Liang, Jinsheng
    Cao, Yichen
    Chen, Yan
    Gainor, Justin F.
    Friboulet, Luc
    Dagogo-Jack, Ibiayi
    Myers, David T.
    Labrot, Emma
    Ruddy, David
    Parks, Melissa
    Lee, Dana
    DiCecca, Richard H.
    Moody, Susan
    Hao, Huaixiang
    Mohseni, Morvarid
    LaMarche, Matthew
    Williams, Juliet
    Hoffmaster, Keith
    Caponigro, Giordano
    Benes, Cyril H.
    Shaw, Alice T.
    Hata, Aaron N.
    Li, Fang
    Engelman, Jeffrey A.
    CANCER RESEARCH, 2017, 77
  • [45] Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
    Califano, Raffaele
    Greystoke, Alastair
    Lal, Rohit
    Thompson, Joyce
    Popat, Sanjay
    LUNG CANCER, 2017, 111 : 51 - 58
  • [46] Development of an ALK vaccine to treat ALK-rearranged non-small cell lung cancers
    Blasco, Rafael B.
    CANCER IMMUNOLOGY RESEARCH, 2016, 4 (11)
  • [47] PROGNOSTIC FACTORS AND OUTCOMES OF PATIENTS WITH CENTRAL NERVOUS SYSTEM (CNS) METASTATIC ALK-REARRANGED NON-SMALL CELL LUNG CANCER (NSCLC)
    Kachur, Ekaterina
    Reiss, Samantha
    Land, Josiah
    Buie, Larry
    Reiner, Anne
    Panageas, Katherine
    Riely, Gregory
    Pentsova, Elena
    NEURO-ONCOLOGY, 2017, 19 : 40 - 40
  • [48] Variation in health-related quality of life (HRQoL) during chemotherapy for advanced non-small cell lung cancer.
    Gronberg, Bjorn Henning
    Sorhaug, Sveinung
    Hjelde, Harald Harris
    Stene, Guro Birgitte
    Amundsen, Tore
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [49] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shaw, Alice T.
    Kim, Dong-Wan
    Mehra, Ranee
    Tan, Daniel S. W.
    Felip, Enriqueta
    Chow, Laura Q. M.
    Camidge, D. Ross
    Vansteenkiste, Johan
    Sharma, Sunil
    De Pas, Tommaso
    Riely, Gregory J.
    Solomon, Benjamin J.
    Wolf, Juergen
    Thomas, Michael
    Schuler, Martin
    Liu, Geoffrey
    Santoro, Armando
    Lau, Yvonne Y.
    Goldwasser, Meredith
    Boral, Anthony L.
    Engelman, Jeffrey A.
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (13): : 1189 - 1197
  • [50] Ceritinib in ALK-Rearranged Non-Small-Cell Lung Cancer
    Shen, Liang
    Ji, Hong-Fang
    NEW ENGLAND JOURNAL OF MEDICINE, 2014, 370 (26): : 2537 - 2537
12345